Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone

NCT04764630 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

FED

Sponsor class

Conditions

Healthy Subjects
Opioid Antagonist
Pharmacokinetics

Interventions

DRUG: Four naloxone nasal spray doses (1 every 2.5 min)
DRUG: Four naloxone nasal spray doses (2 every 2.5 min)
DRUG: Two naloxone nasal spray doses (1 every 2.5 min)

Sponsor

Food and Drug Administration (FDA)

Collaborators

[object Object]